​
​

Context Therapeutics (CNTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CNTX Stock Forecast

Context Therapeutics stock forecast is as follows: an average price target of $5.25 (represents a 218.18% upside from CNTX’s last price of $1.65) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

CNTX Price Target

The average price target for Context Therapeutics (CNTX) is $5.25 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $4.50. This represents a potential 218.18% upside from CNTX's last price of $1.65.

CNTX Analyst Ratings

Buy

According to 2 Wall Street analysts, Context Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CNTX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Context Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 08, 2024Emily BodnarH.C. Wainwright$6.00$2.34156.41%263.64%
May 16, 2024Joseph CatanzaroPiper Sandler$4.50$1.69166.27%172.73%
May 09, 2024Emily BodnarH.C. Wainwright$5.00$1.81176.24%203.03%
Row per page
Go to

The latest Context Therapeutics stock forecast, released on Aug 08, 2024 by Emily Bodnar from H.C. Wainwright, set a price target of $6.00, which represents a 156.41% increase from the stock price at the time of the forecast ($2.34), and a 263.64% increase from CNTX last price ($1.65).

Context Therapeutics Price Target by Period

1M3M12M
# Anlaysts--3
Avg Price Target--$5.17
Last Closing Price$1.65$1.65$1.65
Upside/Downside-100.00%-100.00%213.33%

In the current month, the average price target of Context Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Context Therapeutics's last price of $1.65. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 24, 2024H.C. WainwrightBuyBuyHold
Sep 16, 2024Piper SandlerOverweightOverweightHold
Aug 08, 2024H.C. WainwrightBuyBuyHold
May 16, 2024Piper Sandler-OverweightInitialise
May 09, 2024H.C. WainwrightBuyBuyHold
Row per page
Go to

Context Therapeutics's last stock rating was published by H.C. Wainwright on Sep 24, 2024. The company gave CNTX a "Buy" rating, the same as its previous rate.

Context Therapeutics Financial Forecast

Context Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Context Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CNTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Context Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict CNTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Context Therapeutics's previous annual EBITDA (undefined) of $NaN.

Context Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-5.63M$-5.63M$-4.83M$-4.83M$-4.56M$-7.24M$-3.66M
High Forecast$-5.63M$-5.63M$-4.83M$-4.83M$-3.65M$-7.24M$-3.66M
Low Forecast$-5.63M$-5.63M$-4.83M$-4.83M$-5.47M$-7.24M$-3.66M
Surprise %-------

Context Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CNTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Context Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Context Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CNTX last annual SG&A of $NaN (undefined).

Context Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-0.07$-0.07$-0.06$-0.06$-0.06$-0.09$-0.07
High Forecast$-0.07$-0.07$-0.06$-0.06$-0.05$-0.09$-0.07
Low Forecast$-0.07$-0.07$-0.06$-0.06$-0.07$-0.09$-0.07
Surprise %-------

According to undefined Wall Street analysts, Context Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CNTX previous annual EPS of $NaN (undefined).

Context Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
INABIN8bio$0.32$14.004275.00%Buy
CHRSCoherus BioSciences$0.82$9.00997.56%Hold
XFORX4 Pharmaceuticals$0.37$3.67891.89%Buy
SPROSpero Therapeutics$1.16$10.00762.07%Buy
CTMXCytomX Therapeutics$0.89$5.73543.82%Buy
INZYInozyme Pharma$2.81$14.67422.06%Buy
CNTXContext Therapeutics$1.65$5.25218.18%Buy
ZURAZura Bio$3.15$10.00217.46%Buy
ABOSAcumen Pharmaceuticals$2.39$7.00192.89%Buy
DAWNDay One Biopharmaceuticals$13.52$38.80186.98%Buy
ANNXAnnexon$5.46$14.00156.41%Buy
TERNTerns Pharmaceuticals$5.91$14.25141.12%Buy
ASMBAssembly Biosciences$15.34$35.50131.42%Buy
NXTCNextCure$1.31$3.00129.01%Buy
BOLTBolt Biotherapeutics$0.56$1.0078.57%Hold
WVEWave Life Sciences$14.21$22.1455.81%Buy
AMLXAmylyx Pharmaceuticals$5.22$6.6727.78%Buy
VECTVectivBio$16.87$18.006.70%Buy
GRCLGracell Bio$10.25$6.00-41.46%Buy

CNTX Forecast FAQ

Is Context Therapeutics a good buy?

Yes, according to 2 Wall Street analysts, Context Therapeutics (CNTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of CNTX's total ratings.

What is CNTX's price target?

Context Therapeutics (CNTX) average price target is $5.25 with a range of $4.5 to $6, implying a 218.18% from its last price of $1.65. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Context Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CNTX stock, the company can go up by 218.18% (from the last price of $1.65 to the average price target of $5.25), up by 263.64% based on the highest stock price target, and up by 172.73% based on the lowest stock price target.

Can Context Therapeutics stock reach $2?

CNTX's average twelve months analyst stock price target of $5.25 supports the claim that Context Therapeutics can reach $2 in the near future.

What are Context Therapeutics's analysts' financial forecasts?

Context Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-15.468M (high $-14.556M, low $-16.38M), average SG&A $0 (high $0, low $0), and average EPS is $-0.213 (high $-0.202, low $-0.225). CNTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-20.925M (high $-20.925M, low $-20.925M), average SG&A $0 (high $0, low $0), and average EPS is $-0.26 (high $-0.26, low $-0.26).